July 31, 2020: NTRC launches www.residencetimer.com for biochemical assays in drug discovery.
Biochemical assays for determination of binding characteristics
Oss, July, 31, 2020 – NTRC Precision Medicine Services proudly launches its new and dedicated website for biochemical assays, www.residencetimer.com. The website presents services for the determination of binding characteristics of drug candidates to their target. The services include ResidenceTimer™, QuickScout™ and Molecular Interactions. ResidenceTimer™ determines the target residence time of a drug candidate to its target via Surface Plasmon Resonance, using Biacore. Determination of target residence time may help to differentiate drug candidates from competitor compounds. Drugs that reside on their target for several hours will have the advantage that their pharmacodynamic effect will last even after the drug has been eliminated from systemic circulation. QuickScout™ consists of kinase activity assays for panels of kinases. It allows rapid and accurate determination of the selectivtiy of your compounds. The screening panels range from a full kinase panel comprising more than 300 kinase enzyme assays to focused panels such as the Tyrosine Kinase (TK) panel, the Serine/Threonine Kinase (STK) panel and the Cell Cycle panel. Molecular Interactions concerns broad biochemical characterization of inhibitor-target interactions via tailored assays. The biochemical techniques have been developed to select the best drug candidate for further analysis, for instance by determination of biochemical potency through activity assays based on absorbance, fluorescence, chemiluminescence, TR-FRET or Alpha Technology, determination of protein stabilization via thermal stability assays, and determination of inhibitor binding mode through crystallization of your target with inhibitors.
NTRC is a precision medicine company dedicated to discovering new anti cancer drug candidates. We help you to find a mechanistic hypothesis before entering the clinic. We can study a wide range of cancer cells, primary patient material and immune cells in vitro, in isolation and in coculture, after exposure to monotherapy and combination therapy. In addition, we perform in-depth mechanistic analyses in cells and by biophysical methods, such as Biacore and LC-MS/MS. Keywords are: Quality. Flexibility. Short Turnaround Time.